- Home
- CNTB vs TIL Comparison
CNTB vs TIL Comparison
Compare CNTB & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- TIL
- Stock Information
- Founded
- CNTB 2012
- TIL 2018
- Country
- CNTB United States
- TIL United States
- Employees
- CNTB N/A
- TIL N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- TIL Health Care
- Exchange
- CNTB Nasdaq
- TIL Nasdaq
- Market Cap
- CNTB 114.8M
- TIL 177.1M
- IPO Year
- CNTB 2021
- TIL 2021
- Fundamental
- Price
- CNTB $1.57
- TIL $24.10
- Analyst Decision
- CNTB Strong Buy
- TIL Buy
- Analyst Count
- CNTB 2
- TIL 6
- Target Price
- CNTB $7.50
- TIL $120.50
- AVG Volume (30 Days)
- CNTB 188.4K
- TIL 142.0K
- Earning Date
- CNTB 09-05-2025
- TIL 11-12-2025
- Dividend Yield
- CNTB N/A
- TIL N/A
- EPS Growth
- CNTB N/A
- TIL N/A
- EPS
- CNTB N/A
- TIL N/A
- Revenue
- CNTB $1,965,000.00
- TIL N/A
- Revenue This Year
- CNTB N/A
- TIL N/A
- Revenue Next Year
- CNTB N/A
- TIL N/A
- P/E Ratio
- CNTB N/A
- TIL N/A
- Revenue Growth
- CNTB N/A
- TIL N/A
- 52 Week Low
- CNTB $1.56
- TIL $10.80
- 52 Week High
- CNTB $2.20
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- CNTB 39.75
- TIL 42.77
- Support Level
- CNTB $1.63
- TIL $22.67
- Resistance Level
- CNTB $1.79
- TIL $33.83
- Average True Range (ATR)
- CNTB 0.18
- TIL 2.45
- MACD
- CNTB -0.04
- TIL -0.55
- Stochastic Oscillator
- CNTB 0.39
- TIL 12.81
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.